Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 3—March 2013

Research

Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection

Max R. O’DonnellComments to Author , Nesri Padayatchi, Charlotte Kvasnovsky, Lise Werner, Iqbal Master, and C. Robert Horsburgh
Author affiliations: Author affiliations: Albert Einstein College of Medicine, Bronx, New York, USA (M.R. O’Donnell); Centre for AIDS Programme of Research in South Africa, Durban, South Africa (M.R. O’Donnell, N. Padayatchi, L. Werner); University of Maryland School of Medicine, Baltimore, Maryland, USA (C. Kvasnovsky); King George V Hospital, Sydenham, South Africa (I. Master); Boston University School of Public Health, Boston, Massachusetts, USA (C.R. Horsburgh, Jr.); Boston University School of Medicine, Boston (C.R. Horsburgh, Jr.)

Main Article

Table 3

Predictors of 49 deaths at 24 months of treatment for 114 HIV-positive and HIV-negative XDR TB patients, KwaZulu-Natal Province, South Africa*

Predictor No. died/total no. (%) Univariate analysis
Multivariate analysis†
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Sex
F 27/65 (41.5) 0.88 (0.50–1.54) 0.6484 0.95 (0.51–1.77) 0.8611
M
22/49 (44.9)
1.0 (referent)
NA

1.0 (referent)
NA
Age, y
<36 25/58 (43.1) 1.03 (0.59–1.80) 0.9285 NA NA
>36
24/56 (42.9)
1.0 (referent)
NA

NA
NA
Previous TB treatment‡
Yes 38/92 (41.3) 1.47 (0.53–4.13) 0.4614 1.28 (0.45–3.65) 0.6391
No 4/15 (26.7) 1.0 (referent) NA 1.0 (referent) NA
Unknown
7/7 (100)
NA
NA

NA
NA
Initial sputum smear result
Positive 30/67 (44.8) 1.05 (0.59–1.86) 0.8704 NA NA
Negative
19/47 (40.4)
1.0 (referent)
NA

NA
NA
HIV status‡
Positive 36/82 (43.9) 1.14 (0.58–2.25) 0.6971 1.30 (0.61–2.78) 0.4966
Negative 11/25 (44.0) 1.0 (referent) NA 1.0 (referent)
Unknown
2/7 (28.6)
NA
NA

NA
NA
Adverse event
Yes 23/52 (44.2) 1.02 (0.58–1.79) 0.9420 NA NA
No 26/62 (41.9) 1.0 (referent) NA NA NA

*XDR TB, extensively drug-resistant tuberculosis; NA, not applicable.
†Significant variables or variables that caused >10% change in the bivariate hazard ratio were included in the multivariate model.
‡Patients whose HIV status or previous TB treatment history was unknown were excluded from analyses.

Main Article

TOP